Introduction

Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of receptors and is overexpressed in 15–20% of breast cancer. Considered a prognostic and predictive marker of breast cancer, HER2 is highly aggressive and significantly reduces disease-free and overall survival [1, 2].

Two therapeutic approaches are used to inhibit HER2-mediated signaling. The first approach is trastuzumab, a humanized monoclonal antibody that blocks the activity of HER2, which improves the prognosis of early and advanced stage HER2-positive breast cancer [3]. The second approach is lapatinib, an orally active small molecule that reversibly inhibits HER1 and HER2, best studied in clinical trials to date. Lapatinib is often administered in combination with endocrine therapy or with capecitabine [4]. Trastuzumab offers better pathological complete response (pCR) rates with no additional toxicity when administered with neoadjuvant chemotherapy for the treatment of HER2-positive breast cancer [5]. Preclinical studies of the trastuzumab and lapatinib combination have also suggested that dual targeting is more effective than single-agent targeting [6]. Assessment of the clinical benefit of
administering the lapatinib and trastuzumab combination with chemotherapy for operable HER2-positive breast cancer has proved positive [7], but replacement of lapatinib with trastuzumab as first-line targeted therapy in breast cancer has demonstrated conflicting results. Neoadjuvant chemotherapy is the standard treatment for women who present with large, locally advanced breast tumors.

A meta-analysis of all relevant published randomized, controlled trials (RCTs) was performed to compare the efficiency and safety of lapatinib and trastuzumab, alone or in combination, administered with neoadjuvant chemotherapy in patients with HER2-positive breast cancer.

**Patients and methods**

**Search strategy and study selection**

The search strategy consisted of a systematic review of the literature for RCTs over the last 5 years in any language in the Wanfang Data, PubMed, the Cochrane Library, Medline, and EBSCO databases. The publication time searched was from March 2011 to March 2016. The search terms used were “trastuzumab,” “lapatinib,” “her-2 positive,” “breast AND (cancer OR tumor OR carcinoma),” and “randomized controlled trials OR RCT.” Article selection was based on the methodology used in the RCTs. A total of 39 Chinese articles and 506 English articles were identified. These articles were reviewed and screened for duplicate or incomplete data. When relevant data were unclear, the articles were read by different investigators and then discussed.

**Data extraction**

Inclusion criteria were RCTs that (1) pathologically confirmed breast cancer and HER2 positivity, (2) patients aged over 18 years, (3) chemotherapy tolerance, (4) expected lifetime of more than 3 months, (5) compared trastuzumab with lapatinib or trastuzumab versus the combination therapy, and (6) reported sufficient data on outcomes. Exclusion criteria were (1) nonrandomized and nonclinical controlled trials, (2) trials with missing data, and (3) duplicate reports, trials of poor methodological quality and trials with obvious bias.

Data extracted from each article included the name of the first author, year of publication, journal name, study quality, intervention, number of patients in the study, dosage used in the three groups (lapatinib, trastuzumab, and combination therapy), and the number of patients with different endpoints.

Several outcomes were measured: pCR, neutropenia, diarrhea, dermatologic toxicity, and congestive heart failure (CHF). pCR was defined as the absence of any invasive component in the resected breast specimen. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria Version 3.0. The number of patients with grade 3–4 adverse events was determined from the articles. Disagreement regarding data extraction was resolved by discussion and consensus among the investigators.

**Quality assessment**

The methodological quality of the RCTs was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0: (1) random sequence generation, (2) concealment of allocation, (3) blinding of participants and personnel, (4) blinding of the outcome assessment, (5) incomplete outcome data, (6) selective reporting, and (7) other sources of bias.

**Statistical methods**

Data were analyzed using Review Manager v.5.3 software (Cochrane Collaboration, Oxford, UK). For dichotomous variables, outcomes were calculated as the relative risk ratio (RR), the 95% confidence interval (CI), and a P-value of <0.05 was considered statistically significant. The inconsistency index ($I^2$) statistic and the Q statistic were used to test the heterogeneity between RCTs [7]. For outcomes with fine homogeneity ($P > 0.1; I^2 \leq 50$), a fixed effect model was used for secondary analysis; otherwise ($P < 0.1; I^2 > 50$), a random-effect model was used [7].

**Results**

**Included studies**

A total of 39 Chinese papers and 506 English papers were selected, published from March 2011 to March 2016. The literature selection process is presented in the PRISMA flowchart (Fig. 1) according to the PRISMA guidelines. After comprehensive discussion and analysis of the full text, eight RCTs were selected and included in the final meta-analysis.

The selected RCTs included a total of 2350 patients with pathologically confirmed breast cancer. Of these patients, 837 received lapatinib, 913 received trastuzumab, and 555 received the combination therapy. Each RCT applied different modes of neoadjuvant therapy and different doses of experimental drugs. Table 1 presents the characteristics of the RCTs.

**Methodological quality**

Five RCTs referred to restricted randomization methods, such as permuted blocks design or biased-coin algorithm.
Seven RCTs included patients who discontinued treatment because they refused surgery or did not meet the test requirements (Fig. 2). The funnel plot, which was substantially symmetrical, was used to analyze the publication bias (Fig. 3). Considering that the meta-analysis involves a relatively small number of RCTs, a certain degree of publication bias exists.

**Pathological complete response rate**

The pCR rate was analyzed in eight studies including 1750 patients (n = 837 in the lapatinib group; n = 913 in the trastuzumab group). The heterogeneity test was not statistically significant; therefore, data for each outcome was calculated using the fixed effects model (I² = 26%; P = 0.22). The meta-analysis indicated a significant difference in the pCR rate in patients treated with trastuzumab compared to lapatinib (RR = 0.82, 95% CI: 0.73–0.93; Z = 3.00; P = 0.003) (Fig. 4). Six studies administering combination therapy (n = 555 in both groups) were also analyzed. Compared to trastuzumab alone, combination therapy showed a higher pCR rate (RR = 1.33, 95% CI: 1.18–1.50; Z = 4.70; P < 0.00001) (Fig. 4).

**Neutropenia**

The random effects model was used to assess the neutropenia adverse event between the lapatinib and trastuzumab groups as the heterogeneity test was significant.
(I² = 68%; P = 0.009). The six studies included in the meta-analysis indicated no significant difference in the neutropenia adverse event between the lapatinib and trastuzumab group (RR = 1.21, 95% CI: 0.71–2.06; Z = 0.69; P = 0.49) (Fig. 5).

The random effects model was also used to assess the neutropenia adverse event between the trastuzumab and the combination groups as the heterogeneity test was significant (I² = 29%; P = 0.24). The four studies included in the meta-analysis indicated no significant difference in the neutropenia adverse event in patients between the trastuzumab and combination groups (RR = 1.38, 95% CI: 0.82–2.31; Z = 1.22; P = 0.22) (Fig. 6).

**Diarrhea**

The fixed effects model was used to analyze the diarrhea adverse event between the lapatinib and trastuzumab groups as the heterogeneity test was not significant (I² = 0%; P = 0.81). The seven studies included in the meta-analysis indicated a significant difference in the diarrhea adverse event in patients between the lapatinib and trastuzumab groups (RR = 7.55, 95% CI: 4.74–12.02; Z = 8.51; P < 0.00001) (Fig. 5).

The fixed effects model was also used to analyze the diarrhea adverse event between the trastuzumab and combination groups as the heterogeneity test was not significant (I² = 0%; P = 1.00). The four studies included in the meta-analysis indicated a significant difference in the diarrhea adverse event in patients between the trastuzumab and combination groups (RR = 14.59, 95% CI: 7.69–27.67; Z = 8.20; P < 0.00001) (Fig. 6).

**Dermatologic toxicity**

The fixed effects model was used to analyze the diarrhea adverse event between the lapatinib and trastuzumab groups as the heterogeneity test was not significant (I² = 18%; P = 0.30). The seven studies included in the meta-analysis indicated a significant difference in the dermatologic toxicity in patients between the lapatinib and trastuzumab groups (RR = 5.14, 95% CI: 2.85–9.26; Z = 5.45; P < 0.00001) (Fig. 5).

The random effects model was used to analyze the diarrhea adverse event between the trastuzumab and combination groups as the heterogeneity test was not significant (I² = 0%; P = 0.79). The five studies included in the meta-analysis indicated a significant difference in the dermatologic toxicity in patients between the trastuzumab and combination groups (RR = 3.10, 95% CI: 1.61–5.96; Z = 3.39; P = 0.007) (Fig. 6).

**Congestive heart failure**

The fixed effects model was used to analyze the diarrhea adverse event between the lapatinib and trastuzumab groups as the heterogeneity test was not significant (I² = 0%; P = 0.81). The seven studies included in the meta-analysis indicated a significant difference in the diarrhea adverse event in patients between the trastuzumab and combination groups (RR = 1.21, 95% CI: 0.71–2.06; Z = 0.69; P = 0.49) (Fig. 5).

The random effects model was also used to assess the neutropenia adverse event between the trastuzumab and the combination groups as the heterogeneity test was significant (I² = 29%; P = 0.24). The four studies included in the meta-analysis indicated no significant difference in the neutropenia adverse event in patients between the trastuzumab and combination groups (RR = 1.38, 95% CI: 0.82–2.31; Z = 1.22; P = 0.22) (Fig. 6).

**Diarrhea**

The fixed effects model was used to analyze the diarrhea adverse event between the lapatinib and trastuzumab groups as the heterogeneity test was not significant (I² = 0%; P = 0.81). The seven studies included in the meta-analysis indicated a significant difference in the diarrhea adverse event in patients between the lapatinib and trastuzumab groups (RR = 7.55, 95% CI: 4.74–12.02; Z = 8.51; P < 0.00001) (Fig. 5).

The fixed effects model was also used to analyze the diarrhea adverse event between the trastuzumab and combination groups as the heterogeneity test was not significant (I² = 0%; P = 1.00). The four studies included in the meta-analysis indicated a significant difference in the diarrhea adverse event in patients between the trastuzumab and combination groups (RR = 14.59, 95% CI: 7.69–27.67; Z = 8.20; P < 0.00001) (Fig. 6).

**Dermatologic toxicity**

The fixed effects model was used to analyze the diarrhea adverse event between the lapatinib and trastuzumab groups as the heterogeneity test was not significant (I² = 18%; P = 0.30). The seven studies included in the meta-analysis indicated a significant difference in the dermatologic toxicity in patients between the lapatinib and trastuzumab groups (RR = 5.14, 95% CI: 2.85–9.26; Z = 5.45; P < 0.00001) (Fig. 5).

The random effects model was used to analyze the diarrhea adverse event between the trastuzumab and combination groups as the heterogeneity test was not significant (I² = 0%; P = 0.79). The five studies included in the meta-analysis indicated a significant difference in the dermatologic toxicity in patients between the trastuzumab and combination groups (RR = 3.10, 95% CI: 1.61–5.96; Z = 3.39; P = 0.007) (Fig. 6).

**Congestive heart failure**

The fixed effects model was used to analyze the diarrhea adverse event between the lapatinib and trastuzumab groups as the heterogeneity test was not significant (I² = 0%; P = 0.81). The seven studies included in the meta-analysis indicated a significant difference in the diarrhea adverse event in patients between the trastuzumab and combination groups (RR = 1.21, 95% CI: 0.71–2.06; Z = 0.69; P = 0.49) (Fig. 5).

The random effects model was also used to assess the neutropenia adverse event between the trastuzumab and the combination groups as the heterogeneity test was significant (I² = 29%; P = 0.24). The four studies included in the meta-analysis indicated no significant difference in the neutropenia adverse event in patients between the trastuzumab and combination groups (RR = 1.38, 95% CI: 0.82–2.31; Z = 1.22; P = 0.22) (Fig. 6).
as the heterogeneity test was not significant ($I^2 = 0\%$; $P = 0.33$). The five studies included in the meta-analysis indicated no significant difference in the CHF in patients between the lapatinib and trastuzumab groups (RR = 1.31, 95% CI: 0.49–3.47; $Z = 0.54; P = 0.59$) (Fig. 5).

Only three studies included both the trastuzumab and the combination groups described the outcome, which indicated no significant difference in CHF in patients between the trastuzumab and the combination groups (RR = 0.14, 95% CI: 0.02–1.17; $Z = 1.02; P = 0.07$) (Fig. 6).

**Discussion**

This study compared the efficiency and safety of lapatinib and trastuzumab, alone or in combination, combined with neoadjuvant chemotherapy in patients with HER2-positive breast cancer. The meta-analysis provided evidence that lapatinib and trastuzumab combination therapy significantly increased the pCR rate. Trastuzumab increased the pCR rate more than lapatinib. Lapatinib caused skin rash, diarrhea, and other adverse events.

Neoadjuvant chemotherapy has been reported to be equivalent to adjuvant chemotherapy in terms of survival and overall disease progression in the treatment of breast cancer [8]. Neoadjuvant therapy is widely used in the treatment of breast cancer and its clinical application offers certain attractive advantages: first, the treatment reduces tumor size and increases breast-conserving surgery rates; second, it provides an intuitive evaluation for predicting treatment efficacy; third, it evaluates patient prognosis as the pCR rate is a proven reliable prognostic
Lapatinib and Trastuzumab in HER2-Positive Breast Cancer

Y. Xin et al.

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Trastuzumab substantially improves the efficacy of chemotherapy in HER2-positive breast cancer patients. Resistance to trastuzumab still develops in some women after adjuvant therapy, which increases the importance of the development of additional agents that target HER2 through different mechanisms of action [6]. Lapatinib is efficient in patients with HER2-positive metastatic breast cancer that progressed after trastuzumab treatment. When trastuzumab fails in the target treatment, second-line therapy with lapatinib is 8% efficient [12]. As trastuzumab and lapatinib act on different parts of the HER2 receptor, the therapies are complementary in principle and in mechanism. Preclinical experiments have confirmed that the combination of these two drugs synergistically inhibit breast cancer cell growth and enhance the HER2 blocking effect [13]. In addition, comprehensive anti-HER2 therapy appears to reduce HER2 resistance [14].

In the eight RCTs, the pCR rate as the first endpoint was analyzed for the lapatinib, trastuzumab, and combination groups. A significant difference in the pCR rate between

| Study or Subgroup | L Events | T Events | Weight | M-H, Fixed, 95% CI |
|-------------------|----------|----------|--------|------------------|
| Alba E 2014       | 13       | 51       | 25     | 48               | 7.7% [0.84, 0.58] |
| BaselgaJ 2012     | 38       | 154      | 44     | 149              | 13.4% [0.12, 0.21] |
| Bonneter H 2015   | 10       | 22       | 27     | 52               | 4.8% [0.14, 0.28] |
| Carey L 2013      | 20       | 64       | 54     | 118              | 11.4% [0.45, 1.03] |
| Guarnieri 2012    | 10       | 38       | 9      | 36               | 2.8% [0.48, 2.29] |
| Holmes FA 2013    | 13       | 29       | 14     | 26               | 4.4% [0.49, 1.43] |
| Robidoux A 2013   | 91       | 171      | 93     | 177              | 27.4% [0.83, 1.24] |
| Unich M 2012      | 70       | 308      | 93     | 307              | 26.0% [0.57, 0.98] |
| Total (95% CI)    | 837      | 913      | 100%   | 0.82 [0.73, 0.93] |

Test for overall effect: Z = 3.00 (P = 0.003)

**Figure 3.** Funnel plot of the publication bias.

**Figure 4.** Forest plot of the pCR rate for lapatinib, trastuzumab, and combination therapy.

| Study or Subgroup | L+T Events | T Events | Weight | M-H, Fixed, 95% CI |
|-------------------|------------|----------|--------|------------------|
| BaselgaJ 2012     | 78         | 152      | 44     | 149              | 16.8% [2.33, 1.30] |
| Bonneter H 2015   | 29         | 48       | 27     | 52               | 10.9% [1.65, 0.82] |
| Carey L 2013      | 65         | 116      | 54     | 117              | 23.0% [1.56, 0.94] |
| Guarnieri 2012    | 21         | 45       | 9      | 36               | 4.2% [3.56, 0.98] |
| Holmes FA 2013    | 17         | 23       | 14     | 26               | 5.5% [2.11, 0.89] |
| Robidoux A 2013   | 106        | 171      | 93     | 177              | 38.3% [1.42, 0.98] |
| Total (95% CI)    | 555        | 557      | 100%   | 1.33 [1.50, 1.18] |

Test for overall effect: Z = 4.70 (P < 0.0001)

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Figure 5. Forest plot of the adverse events for lapatinib and trastuzumab: (A) neutropenia, (B) diarrhea, (C) dermatologic toxicity, (D) congestive heart failure.
NSABP [6] trials, the pCR rates in the lapatinib group were slightly higher than in the trastuzumab group, which may be explained by the relatively small number of patients analyzed, and the variation in dosage and courses of the targeted drugs among the trials. The results of this study demonstrated that combination therapy is better than trastuzumab alone in increasing the pCR rate.

The meta-analysis analyzed grade 3–4 adverse events according to the national criteria. Common adverse reactions of lapatinib were diarrhea and skin rash while trastuzumab showed potentially serious cardiac toxicity. The incidence of adverse events, such as diarrhea and skin rash, in the lapatinib group was significantly higher than in the trastuzumab group. Lapatinib and trastuzumab...
combination therapy also exhibited the same effect. Surprisingly, the results demonstrated that the combination did not increase cardiac toxicity compared to trastuzumab, which indicates that combination therapy is safe and effective.

This meta-analysis had several limitations. As shown in Table 1, only a limited number of eligible studies and a relatively small number of patients were analyzed. Each study used different drug doses and different neoadjuvant therapy programs. Of the eight English-language RCTs, five [3, 6, 15, 18, 19] referred to restricted randomization methods, such as permuted blocks design or biased-coin algorithm, while the other RCTs [16, 17, 20] did not specify the random allocation method. As positive results are more likely to be published, publication bias should also be considered. In addition, eight studies were randomized, open-label, multicenter trials. Participants and investigators were not blinded to the therapy assignment, but researchers accessing the outcome were blinded to the therapy group. As outcomes including pCR, neutropenia, diarrhea, dermatologic toxicity, and CHF are objective, the lack of blinding of participants and investigators would not have caused significant bias.

In conclusion, the currently available evidence shows that lapatinib and trastuzumab combination therapy significantly increases pCR rates in HER2-positive breast cancer patients with no additional cardiac side effects compared to trastuzumab alone. Trastuzumab is better than lapatinib according to the pCR rate from our data. However, trastuzumab is still the first-line targeted therapy in breast cancer and cannot be replaced by lapatinib because of cost considerations. Large, high-quality, double-blind trials are needed to confirm the efficiency of lapatinib and trastuzumab combination therapy, and verify whether combination therapy can prolong disease-free survival or overall survival.

Conflict of Interest
The authors declare that they have no conflict of interest.

References
1. Valachis, A., A. Nearchou, P. Lind, and D. Mauri. 2012. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence. Breast Cancer Res. Treat. 135:655–662.
2. Ross, J. S., E. A. Slodkowska, W. F. Symmans, L. PusztaI, P. M. Ravdin, and G. N. Hortobagyi. 2009. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368.
3. Guarneri, V., A. Frassoldati, A. Bottini, K. Cagossi, G. Bisagni, S. Sarti, et al. 2012. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J. Clin. Oncol. 30:1989–1995.
4. Blackwell, K. L., H. J. Burstein, A. M. Storniolo, H. S. Rugo, G. Sledge, G. Aktan, et al. 2012. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2–positive metastatic breast cancer: final results from the EGF104900 study. J. Clin. Oncol. 30:2585–2592.
5. Sun, J., C. Chen, X. Yao, and S. Sun. 2015. Lapatinib combined with neoadjuvant paclitaxel trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2–positive breast cancer: a meta-analysis of randomized controlled trials. Oncol. Lett. 9:1351–1358.
6. Robidoux, A., G. Tang, P. Rastogi, C. E. Geyer Jr, C. A. Azar, J. N. Atkins, et al. 2013. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 14:1183–1192.
7. Hicks, M., E. R. Macrae, M. Abdel-Rasoul, R. Layman, S. Friedman, J. Querry, et al. 2015. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical. Oncologist 20:337–343.
8. Mauri, D., N. Pavlidis, and J. P. Ioannidis. 2005. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl Cancer Inst. 97:188–194.
9. Cao, M., Y. Wu, N. Lu, and J. Huang. 2015. Meta-analysis of randomized controlled trials between trastuzumab and lapatinib combined with neoadjuvant therapy for breast cancer. Journal of International. Oncology 42:269–273.
10. Rimawi, M. F., S. B. Aleixo, A. A. Rozas, J. Nunes de Matos Neto, M. Caleffi, A. C. Figueira, et al. 2015. Neoadjuvant, randomized, open-label phase ii trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Clin. Breast Cancer 15:101–109.
11. Welslau, M., V. Diersa, J. H. Sohn, S. A. Hurvitz, D. Lalla, L. Fang, et al. 2014. Patient-reported outcomes from EMILLA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer. Cancer 120:642–651.
12. Zhang, Z. 2014. Molecular targeted drugs and progression in breast cancer. Clin. Med. J. 12(z1):52–56.
13. Jiang, Z., Y. Yang, Z. Pan, Z. Yue, and L. Li. 2014. Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis. Zhonghua Yi Xue Za Zhi. 94:3854–3858.
14. Wang, Y. C., G. Morrison, R. Gillihan, J. Guo, R. M. Ward, X. L. Fu, et al. 2011. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers—role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 13:R121.
15. Untch, M., S. Loibl, J. Bischoff, H. Eidtmann, M. Kaufmann, J. U. Blöhmer, et al. 2012. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline–taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 13:135–144.
16. Carey, L., D. Berry, D. Ollila, W. T. Barry, B. N. Pitcher, L. N. Harris, et al. 2016. Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J. Clin. Oncol. 34:542–549.
17. Bonnefoi, H., W. Jacot, M. Saghatelian, C. Moldovan, L. Venat-Bouvet, K. Zaman, et al. 2015. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann. Oncol. 26:325–332.
18. Baselga, J., I. Bradbury, H. Eidtmann, S. Di Cosimo, De Azambuja E., C. Aura, et al. 2012. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633–640.
19. Holmes, F. A., V. Espina, L. A. Liotta, Y. M. Nagarwala, M. Danso, K. J. McIntyre, et al. 2013. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, phosphorylated Stat5, and autophagy protein signaling. BMC Res. Notes 6:507.
20. Alba, E., J. Albanell, J. de la Haba, A. Barnadas, L. Calvo, P. Sánchez-Rovira, et al. 2014. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br. J. Cancer 110:1139–1147.